Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer

Radiation Oncology

Table 4 Univariate and multivariate Cox analyses

Variable	Overall survival						Anal cancer specific survival
	Univariate		Multivariate				Univariate		Multivariate
	Univariate		Model 1		Model 2^a		Univariate		Model 1		Model 2^a
	HR	P	HR	P	HR	P	HR	P	HR	P	HR	P
Male gender	3.0	0.03	5.4	0.002	3.4	0.02	3.1	0.08	5.4	0.02	2.8	0.12
Active smoking	0.7	0.58	.	.	.	.	0.2	0.16	.	.	.	.
Charlson comorbidity index ≥ 1	1.5	0.42	.	.	.	.	1.2	0.82	.	.	.	.
Immunosuppressive disorders	2.2	0.16	.	.	.	.	3.0	0.11	.	.	.	.
Sarcopenia	4.5	0.004	2.7	0.08	3.9	0.01	3.3	0.07	1.8	0.42	3.0	0.10
Age at diagnosis	0.99	0.78	.	.	.	.	0.97	0.36	.	.	.	.
Tumor size (cm)	1.1	0.53	.	.	.	.	1.1	0.42	.	.	.	.
Lymph node metastasis	0.7	0.38	.	.	.	.	1.0	0.97	.	.	.	.
T4	0.9	0.79	.	.	.	.	0.6	0.55	.	.	.	.
White blood cell grade ≥ 3 toxicity	3.3	0.02	4.4	0.02	.	.	4.6	0.054	6.7	0.03	.	.
Time to treatment initiation ≥ 62 days	1.6	0.37	.	.	.	.	1.5	0.59	.	.	.	.
RTT ≥ 5 days longer than optimal	2.6	0.046	3.2	0.02	3.4	0.02	2.8	0.12	.	.	.	.
Omission/dose reduction of second cycle of chemotherapy	1.6	0.37	.	.	.	.	1.3	0.68	.	.	.	.

ISSN: 1748-717X